2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Workforce, Adverse Events, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Hemophilia, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Paroxysmal Nocturnal Hemoglobinuria, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Metabolic Disorders, Iron Deficiency, Iron Overload, B Cell Lymphoma, Research, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4371 Individualized net clinical benefit of extended anticoagulation after first unprovoked venous thromboembolism: A patient-level simulation study

Jeongyeon Cho, PhD, Nathorn Chaiyakunapruk, PharmD, PhD2, Sachin J. Shah, MD, MPH3, David A. Ganz, MD, PhD4, Anna L. Parks, MD5
1 University of Utah Health Care, Salt Lake City, Utah, United States
2 University of Utah Health Care, Salt Lake City, Utah, United States
3 Massachusetts General Hospital, Boston, Massachusetts, United States
4 University of California Los Angeles, Los Angeles, California, United States
5 University of Utah Health Care, Salt Lake City, Utah, United States

Introduction

After completion of initial anticoagulant therapy for a first unprovoked venous thromboembolism (VTE), current guidelines favor extended anticoagulation, but treatment decisions remain challenging because recurrent VTE and bleeding risks vary substantially across individuals. Although reduced-dose direct oral anticoagulants (DOACs) reduce bleeding compared with full-dose therapy during extended anticoagulation, which patients derive meaningful benefit from each strategy relative to treatment discontinuation remains uncertain.

We compared the net clinical benefit of discontinuation, indefinite full-dose anticoagulation, and indefinite reduced-dose anticoagulation after first unprovoked VTE. We hypothesized that reduced-dose anticoagulation would produce the highest expected net clinical benefit.

 

Methods

We developed a probabilistic patient-level microsimulation informed by a prior decision model of extended anticoagulation after unprovoked VTE (Khan et al., Ann Intern Med 2023). The model simulated outcomes among individuals with first unprovoked VTE who had completed 3 months of initial DOAC therapy. We compared 3 treatment strategies following initial therapy: discontinuation, indefinite full-dose anticoagulation, and indefinite reduced-dose anticoagulation. Individual recurrent VTE and major bleeding risks were generated using the validated VTE-PREDICT model. Baseline event rates were derived from published meta-analyses and reduced-dose hazard ratios from the RENOVE trial. The model simulated monthly risks of recurrent VTE, major bleeding, long-term complications (post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension), and competing mortality to estimate quality-adjusted life years (QALYs) over a 5-year horizon. We reported means with 95% credible intervals [CrI] accounting for first- and second-order uncertainty. A two-way equipoise threshold analysis identified regions where strategies differed by ≤0.01 QALYs.

 

Results

Over 5 years, reduced-dose anticoagulation yielded the highest expected QALYs (3.63; 95% CrI, 3.56-3.70) compared with full-dose anticoagulation (3.61; 95% CrI, 3.55-3.68) and discontinuation (3.60; 95% CrI, 3.53-3.67). Compared with discontinuation, full-dose and reduced-dose anticoagulation prevented 204 and 192 recurrent VTE events per 1,000 patients over 5 years, respectively. The corresponding excess major bleeding events were 26 and 2 per 1,000 patients. Despite these differences in recurrent VTE and bleeding events, absolute gains in net clinical benefit were modest; compared with discontinuation, reduced-dose anticoagulation yielded approximately 9 additional quality-adjusted days over 5 years. Broad regions of clinical equipoise (≤0.01 QALYs) remained across recurrent VTE and bleeding risk combinations, with reduced-dose anticoagulation primarily favored among individuals with estimated annual off-anticoagulant VTE recurrence risk exceeding 10%.

 

Conclusion

Reduced-dose extended anticoagulation was associated with the most favorable balance of recurrent VTE prevention and bleeding, but differences in net clinical benefit were small (approximately 9 quality-adjusted days over 5 years compared with discontinuation) and concentrated among patients at higher recurrent VTE risk. The absence of a clearly superior strategy across much of the clinically relevant risk spectrum supports individualized, risk-guided approaches to extended anticoagulation rather than a uniform approach to indefinite therapy.

Anna L. Parks, MD: No relevant conflicts of interest to declare.